Related Experiment Video
Updated: May 6, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Clinical relevance of the interaction when switching non-nucleoside reverse transcriptase inhibitors in patients
Eric Dailly, Clotilde Allavena, Guillaume Deslandes
1Laboratoire de Pharmacologie Clinique, Hotel Dieu, 9 Quai Moncousu, 44093 Nantes Cedex, France. eric.dailly@chu-nantes.fr.
Abstract:
Substitution of a non-nucleoside reverse transcriptase inhibitor (NNRTI) with another drug of the same class combined with nucleoside reverse transcriptase inhibitors is a therapeutic strategy that can improve the tolerability of antiretroviral treatment. According to the pharmacokinetic properties of NNRTIs, this substitution generates pharmacokinetic drug interactions between NNRTIs, which could decrease NNRTI exposure and virological efficacy during the introductory phase of the new NNRTI. Pharmacokinetics and clinical data are reviewed to estimate the risk for switching from efavirenz to nevirapine, efavirenz to etravirine, efavirenz to rilpivirine and nevirapine to rilpivirine.
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Retrovirus Life Cycles
Pharmacokinetics: Drug–Drug Interactions
Inhibitors of Viral Protein Synthesis
Retroviruses
Pharmacokinetics in Pediatric Patients: Drug Excretion

